References

Heart failure: preventing disease and death worldwide

10.1002/ehf2.12005 · 2014 · External reference

KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease

10.1016/j.kint.2023.10.018 · 2024 · External reference

A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation

10.1016/j.jacc.2013.02.092 · 2013 · External reference

Albuminuria is independently associated with cardiac remodeling, abnormal right and left ventricular function, and worse outcomes in heart failure with preserved ejection fraction

10.1016/j.jchf.2014.05.016 · 2014 · External reference

Albuminuria in chronic heart failure: prevalence and prognostic importance

10.1016/s0140-6736(09)61378-7 · 2009 · External reference

The association of chronic kidney disease and microalbuminuria with heart failure with preserved vs. Reduced ejection fraction

10.1002/ejhf.778 · 2017 · External reference

Albuminuria and heart failure: JACC state-of-the-art review

10.1016/j.jacc.2022.10.028 · 2023 · External reference

Albuminuria and dipstick proteinuria for predicting mortality in heart failure: a systematic review and meta-analysis

10.3389/fcvm.2021.665831 · 2021 · External reference

High-normal albuminuria and risk of heart failure in the community

10.1053/j.ajkd.2011.02.391 · 2011 · External reference

A prespecified exploratory analysis from FIDELITY examined finerenone use and kidney outcomes in patients with chronic kidney disease and type 2 diabetes

10.1016/j.kint.2022.08.040 · 2023 · External reference

Empagliflozin in patients with chronic kidney disease

10.1056/nejmoa2204233 · 2023 · External reference

Unmet needs and opportunities for optimal management of patients with type 2 diabetes and chronic kidney disease

10.1016/j.jdiacomp.2023.108418 · 2023 · External reference

The case for early identification and intervention of chronic kidney disease: conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference

10.1016/j.kint.2020.10.012 · 2021 · External reference

2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines

10.1016/j.jacc.2021.12.012 · 2022 · External reference

First morning voids are more reliable than spot urine samples to assess microalbuminuria

10.1681/asn.2008030292 · 2009 · External reference

The diagnostic accuracy of a urine albumin-creatinine ratio point-of-care test for detection of albuminuria in primary care

10.1053/j.ajkd.2012.05.009 · 2012 · External reference

Exercise-induced albuminuria and circadian blood pressure abnormalities in type 2 diabetes

10.5527/wjn.v6.i4.209 · 2017 · External reference

Biological variability of estimated GFR and Albuminuria in CKD

10.1053/j.ajkd.2018.04.023 · 2018 · External reference

Day-to-day variability in spot urine albumin-creatinine ratio

10.1053/j.ajkd.2013.06.016 · 2013 · External reference

Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and kidney disease: improving global outcomes (KDIGO)

10.2337/dci22-0027 · 2022 · External reference

Urine albumin-creatinine ratio variability in people with type 2 diabetes: clinical and research implications

10.1053/j.ajkd.2023.12.018 · 2024 · External reference

Monitoring young people with type 1 diabetes for diabetic nephropathy: potential errors of annual ACR testing

10.1016/j.diabres.2012.12.010 · 2013 · External reference

Visit-to-visit variability in albuminuria predicts renal function deterioration in patients with type 2 diabetes

10.1111/jdi.13761 · 2022 · External reference

KDOQI clinical practice guideline for diabetes and CKD: 2012 update

10.1053/j.ajkd.2012.07.005 · 2012 · External reference

The ratio and difference of urine protein-to-creatinine ratio and albumin-to-creatinine ratio facilitate risk prediction of all-cause mortality

10.1038/s41598-021-86541-3 · 2021 · External reference

Albuminuria and prognosis in CKD: truth be told

10.1053/j.ackd.2011.06.007 · 2011 · External reference

Proteinuria or albuminuria as markers of kidney and cardiovascular disease risk

10.7326/annals-25-02117 · 2025 · External reference

Comparison of different measures of urinary protein excretion for prediction of renal events

10.1681/asn.2010010063 · 2010 · External reference

Diagnostic accuracy of urine dipsticks for detection of albuminuria in the general community

10.1053/j.ajkd.2010.12.026 · 2011 · External reference

Proteinuria versus albuminuria in chronic kidney disease

10.1111/j.1440-1797.2010.01314.x · 2010 · External reference

Conversion of urine protein–creatinine ratio or urine dipstick protein to urine albumin–creatinine ratio for use in chronic kidney disease screening and prognosis: an individual participant–based meta-analysis

10.7326/m20-0529 · 2020 · External reference

Comparison of urine dipstick and albumin: creatinine ratio for chronic kidney disease screening: a population-based study

10.1371/journal.pone.0171106 · 2017 · External reference

From progression to remission: a new paradigm for success in chronic kidney disease

10.1016/j.kint.2025.10.004 · 2025 · External reference

Advancing kidney protection in type 1 diabetes: insights from emerging therapies in type 2 diabetes and chronic kidney disease

10.1080/1744666x.2025.2537446 · 2025 · External reference

Rapid and simultaneous initiation of guideline-directed kidney therapies in patients with CKD and type 2 diabetes

10.1681/asn.0000000752 · 2025 · External reference

Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham heart study

10.1161/circulationaha.105.538132 · 2005 · External reference

Microvascular endothelial dysfunction is associated with albuminuria and CKD in older adults

10.1186/s12882-016-0303-x · 2016 · External reference

Thresholds for pulse wave velocity, urine albumin creatinine ratio and left ventricular mass index using SCORE, Framingham and ESH/ESC risk charts

10.1097/hjh.0b013e328356c579 · 2012 · External reference

Urine albumin excretion is associated with cardiac troponin T detected with a highly sensitive assay in a community-based population

10.1371/journal.pone.0135747 · 2015 · External reference

Albuminuria and endothelial dysfunction in patients with non-diabetic chronic kidney disease

10.12659/msm.903660 · 2017 · External reference

Low-grade albuminuria is associated with left ventricular hypertrophy and diastolic dysfunction in patients with hypertension

10.1159/000500782 · 2019 · External reference

Albuminuria as a marker of systemic congestion in patients with heart failure

10.1093/eurheartj/ehac528 · 2023 · External reference

Microvascular endothelial dysfunction is associated with albuminuria: the Maastricht study

10.1097/hjh.0000000000001674 · 2018 · External reference

Estimated glomerular filtration rate and urinary albumin excretion are independently associated with greater arterial stiffness: the Hoorn study

10.1681/asn.2006111217 · 2007 · External reference

Association between coronary artery calcification progression and microalbuminuria: the MESA study

10.1016/j.jcmg.2010.01.008 · 2010 · External reference

Albuminuria in cardiovascular, kidney, and metabolic disorders: a state-of-the-art review

10.1161/circulationaha.124.071079 · 2025 · External reference

Prevalence of undiagnosed stage 3 chronic kidney disease in France, Germany, Italy, Japan and the USA: results from the multinational observational REVEAL-CKD study

10.1136/bmjopen-2022-067386 · 2023 · External reference

Unresolved reference

External reference

From secondary to primary prevention of progressive renal disease: the case for screening for albuminuria

10.1111/j.1523-1755.2004.66001.x · 2004 · External reference

Trajectories of kidney function in diabetes: a clinicopathological update

10.1038/s41581-021-00462-y · 2021 · External reference

Screening for chronic kidney disease: change of perspective and novel developments

10.1097/mnh.0000000000001016 · 2024 · External reference

Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes. A collaborative meta-analysis of general and high-risk population cohorts

10.1038/ki.2010.531 · 2011 · External reference

Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts

10.1038/ki.2010.550 · 2011 · External reference

Estimated glomerular filtration rate, Albuminuria, and adverse outcomes: an individual-participant data meta-analysis

10.1001/jama.2023.17002 · 2023 · External reference

Changes in GFR and Albuminuria in routine clinical practice and the risk of kidney disease progression

10.1053/j.ajkd.2021.02.335 · 2021 · External reference

Very low-grade albuminuria reflects susceptibility to chronic kidney disease in combination with cardiovascular risk factors

10.1038/hr.2010.39 · 2010 · External reference

Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: a meta-analysis

10.1016/s0140-6736(12)61272-0 · 2012 · External reference

Mild Albuminuria is a risk factor for faster GFR decline in the Nondiabetic population

10.1016/j.ekir.2018.01.015 · 2018 · External reference

High-normal albuminuria and incident chronic kidney disease in a male nondiabetic population

10.1007/s10157-017-1522-6 · 2018 · External reference

Association of Albuminuria with chronic kidney disease progression in persons with chronic kidney disease and Normoalbuminuria

10.7326/m23-2814 · 2024 · External reference

Dapagliflozin in patients with chronic kidney disease

10.1056/nejmoa2024816 · 2020 · External reference

Cardiorenal syndrome: molecular pathways linking cardiovascular dysfunction and chronic kidney disease progression

10.3390/ijms26157440 · 2025 · External reference

Prediction of incident heart failure in CKD: the CRIC study

10.1016/j.ekir.2022.01.1067 · 2022 · External reference

From systemic inflammation to myocardial fibrosis: the heart failure with preserved ejection fraction paradigm revisited

10.1161/circresaha.121.318159 · 2021 · External reference

Systemic interactions in HFpEF: a multiorgan perspective on pathways and therapeutic targets

10.1007/s12265-025-10699-8 · 2025 · External reference

Effect of nesiritide in patients with acute decompensated heart failure

10.1056/nejmoa1100171 · 2011 · External reference

C-reactive protein in heart failure: Prognostic value and the effect of Valsartan

10.1161/circulationaha.104.508465 · 2005 · External reference

Interleukin-6 in patients with heart failure and preserved ejection fraction

10.1016/j.jchf.2023.06.031 · 2023 · External reference

IL-6 and hsCRP predict cardiovascular mortality in patients with heart failure with preserved ejection fraction

10.1002/ehf2.14959 · 2024 · External reference

Inflammatory markers and incident heart failure risk in older adults

10.1016/j.jacc.2009.12.045 · 2010 · External reference

Prevalence and associations of systemic inflammation in heart failure across the Spectrum of ejection fraction

10.1016/j.jchf.2025.102712 · 2026 · External reference

Association between renal function and cardiovascular structure and function in heart failure with preserved ejection fraction

10.1093/eurheartj/ehu254 · 2014 · External reference

Cardiac inflammation contributes to changes in the extracellular matrix in patients with heart failure and normal ejection fraction

10.1161/circheartfailure.109.931451 · 2011 · External reference

Multiple plasma biomarkers for risk stratification in patients with heart failure and preserved ejection fraction

10.1016/j.jacc.2019.12.069 · 2020 · External reference

Urinary albumin excretion in heart failure with preserved ejection fraction: an interim analysis of the CHART 2 study

10.1093/eurjhf/hfs001 · 2012 · External reference

Urinary levels of novel kidney biomarkers and risk of true worsening renal function and mortality in patients with acute heart failure

10.1002/ejhf.746 · 2017 · External reference

Urinary markers in heart failure – types, timing and thresholds

10.1002/ejhf.70079 · 2025 · External reference

Loop diuretics in heart failure: the objective markers to guide the therapy are needed

10.1002/ehf2.14920 · 2024 · External reference

Chronic kidney disease testing among primary care patients with type 2 diabetes across 24 U.S. health care organizations

10.2337/dc20-2715 · 2021 · External reference

Novel prediction equations for absolute risk assessment of total cardiovascular disease incorporating cardiovascular-kidney-metabolic health: a scientific statement from the American Heart Association

10.1161/cir.0000000000001191 · 2023 · External reference

Development and validation of multivariable models to predict mortality and hospitalization in patients with heart failure

10.1002/ejhf.785 · 2017 · External reference

Heart failure risk stratification and efficacy of sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes Mellitus

10.1161/circulationaha.119.042685 · 2019 · External reference

Kidney disease biomarkers improve heart failure risk prediction in the general population

10.1161/circheartfailure.120.006904 · 2020 · External reference

Ten-year risk-prediction equations for incident heart failure hospitalizations in chronic kidney disease: findings from the chronic renal insufficiency cohort study and the multi-ethnic study of atherosclerosis

10.1016/j.cardfail.2021.10.007 · 2022 · External reference

Machine learning to predict the risk of incident heart failure hospitalization among patients with diabetes: the WATCH-DM risk score

10.2337/dc19-0587 · 2019 · External reference

A risk prediction model for heart failure hospitalization in type 2 diabetes mellitus

10.1002/clc.23298 · 2020 · External reference

Elevated urine albumin-to-creatinine ratio increases the risk of new-onset heart failure in patients with type 2 diabetes

10.1186/s12933-023-01796-6 · 2023 · External reference

Rediscovery of the implication of albuminuria in heart failure: emerging classic index for cardiorenal interaction

10.1002/ehf2.14811 · 2024 · External reference

Novel metabolic risk factors for incident heart failure and their relationship with obesity. The MESA (multi-ethnic study of Atherosclerosis)

10.1016/j.jacc.2007.12.048 · 2008 · External reference

Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals

10.1001/jama.286.4.421 · 2001 · External reference

Low-grade albuminuria and the incidence of heart failure in a community-based cohort of elderly men

10.1093/eurheartj/ehm130 · 2007 · External reference

Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy

10.1161/01.cir.0000139860.33974.28 · 2004 · External reference

Association of Albuminuria with 1-year risk of heart failure and other adverse outcomes in atrial fibrillation

10.1161/jaha.125.041185 · 2025 · External reference

Joint association of albuminuria and left ventricular hypertrophy with incident heart failure in adults at high risk with hypertension: a systolic blood pressure intervention trial substudy

10.1016/j.amjcard.2023.09.048 · 2023 · External reference

Prognostic impact of albuminuria in early-stage chronic kidney disease on cardiovascular outcomes: a cohort study

10.1136/heartjnl-2024-324988 · 2025 · External reference

Trajectories of renal biomarkers and new-onset heart failure in the general population: findings from the PREVEND study

10.1002/ejhf.2925 · 2023 · External reference

Longitudinal trajectories of albuminuria and risk of subclinical and clinical heart failure, atrial fibrillation, and coronary heart disease: the MESA study

10.1093/eurjpc/zwaf699 · 2025 · External reference

Association of cardiovascular biomarkers with incident heart failure with preserved and reduced ejection fraction

10.1001/jamacardio.2017.4987 · 2018 · External reference

Association of urine albumin excretion with incident heart failure hospitalization in community-dwelling adults

10.1016/j.jchf.2019.01.016 · 2019 · External reference

Incidence and epidemiology of new onset heart failure with preserved vs. Reduced ejection fraction in a community-based cohort: 11-year follow-up of PREVEND

10.1093/eurheartj/eht066 · 2013 · External reference

Prediction of cardiovascular disease mortality by proteinuria and reduced kidney function: pooled analysis of 39,000 individuals from 7 cohort studies in Japan

10.1093/aje/kws447 · 2013 · External reference

Research priorities for heart failure with preserved ejection fraction: national heart, lung, and blood institute working group summary

10.1161/circulationaha.119.041886 · 2020 · External reference

Prognostic value of Albuminuria and influence of spironolactone in heart failure with preserved ejection fraction

10.1161/circheartfailure.118.005288 · 2018 · External reference

Outcomes of KDIGO-defined CKD in U.S. Veterans with HFpEF, HFmrEF, and HFrEF

10.1016/j.jchf.2024.11.007 · 2025 · External reference

Albuminuria: associated with heart failure severity and impaired clinical outcomes

10.1016/j.cjca.2019.09.001 · 2020 · External reference

Temporal prevalence and prognostic impact of diabetes mellitus and albuminuria in heart failure with preserved ejection fraction

10.1186/s12933-025-02708-6 · 2025 · External reference

Urine albumin-to-creatinine ratio on admission predicts early rehospitalization in patients with acute decompensated heart failure

10.1007/s00380-022-02025-y · 2022 · External reference

Elevated urinary albumin concentration predicts worse clinical outcomes in hospitalized acute decompensated heart failure patients

10.1002/ehf2.13399 · 2021 · External reference

Microalbuminuria and its prognostic significance in patients with acute heart failure with preserved, mid-range, and reduced ejection fraction

10.36660/abc.20201144 · 2022 · External reference

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

10.1056/nejmoa011161 · 2001 · External reference

Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria

10.1161/01.cir.0000146378.65439.7a · 2004 · External reference

Renal outcomes with aliskiren in patients with type 2 diabetes: a prespecified secondary analysis of the ALTITUDE randomised controlled trial

10.1016/s2213-8587(15)00469-6 · 2016 · External reference

Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure

10.1016/j.jchf.2018.02.004 · 2018 · External reference

Short-term changes in albuminuria and risk of cardiovascular and renal outcomes in type 2 diabetes mellitus: a post hoc analysis of the empa-reg outcome trial

10.1161/jaha.120.016976 · 2020 · External reference

Cardiovascular outcomes with Ertugliflozin in type 2 diabetes

10.1056/nejmoa2004967 · 2020 · External reference

Effects of canagliflozin on heart failure outcomes associated with preserved and reduced ejection fraction in type 2 diabetes mellitus: results from the CANVAS program

10.1161/circulationaha.119.040057 · 2019 · External reference

Early change in albuminuria with canagliflozin predicts kidney and cardiovascular outcomes: a post hoc analysis from the credence trial

10.1681/asn.2020050723 · 2020 · External reference

Effect of Finerenone on chronic kidney disease outcomes in type 2 diabetes

10.1056/nejmoa2025845 · 2020 · External reference

Finerenone reduces risk of incident heart failure in patients with chronic kidney disease and type 2 diabetes: analyses from the FIGARO-DKD trial

10.1161/circulationaha.121.057983 · 2022 · External reference

Finerenone and heart failure outcomes by kidney function/Albuminuria in chronic kidney disease and diabetes

10.1016/j.jchf.2022.07.013 · 2022 · External reference

Finerenone and kidney outcomes in patients with heart failure: the FINEARTS-HF trial

10.1016/j.jacc.2024.10.091 · 2025 · External reference

Semaglutide and cardiovascular outcomes in patients with type 2 diabetes

10.1056/nejmoa1607141 · 2016 · External reference

Enalapril prevents clinical proteinuria in diabetic patients with low ejection fraction

10.2337/diacare.23.3.377 · 2000 · External reference

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure

10.1056/nejm199108013250501 · 1991 · External reference

Renoprotective effect of the angiotensin-receptor antagonist Irbesartan in patients with nephropathy due to type 2 diabetes

10.1056/nejmoa011303 · 2001 · External reference

Cardiovascular outcomes in the irbesartan diabetic nephropathy trial of patients with type 2 diabetes and overt nephropathy

10.7326/0003-4819-138-7-200304010-00010 · 2003 · External reference

Is a reduction in albuminuria associated with renal and cardiovascular protection? A post hoc analysis of the ALTITUDE trial

10.1111/dom.12600 · 2016 · External reference

Effect of Sacubitril/Valsartan vs standard medical therapies on plasma NT-proBNP concentration and submaximal exercise capacity in patients with heart failure and preserved ejection fraction: the PARALLAX randomized clinical trial

10.1001/jama.2021.18463 · 2021 · External reference

Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction

10.1002/ejhf.232 · 2015 · External reference

Exploiting the natriuretic peptide pathway to preserve glomerular filtration in heart failure

10.1016/j.jchf.2018.02.017 · 2018 · External reference

Differential effects of β-blockers on albuminuria in patients with type 2 diabetes

10.1161/01.hyp.0000190585.54734.48 · 2005 · External reference

Effect of antihypertensive treatment on qualitative estimates of microalbuminuria

1996 · External reference

Association of empagliflozin treatment with albuminuria levels in patients with heart failure: a secondary analysis of EMPEROR-pooled

10.1001/jamacardio.2022.2924 · 2022 · External reference

Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial

10.1016/s0140-6736(19)32135-x · 2019 · External reference

A comparative post hoc analysis of finerenone and spironolactone in resistant hypertension in moderate-to-advanced chronic kidney disease

10.1093/ckj/sfac234 · 2023 · External reference

Modifiability of composite cardiovascular risk associated with chronic kidney disease in type 2 diabetes with finerenone

10.1001/jamacardio.2023.1505 · 2023 · External reference

Impact of Finerenone-induced albuminuria reduction on chronic kidney disease outcomes in type 2 diabetes

10.7326/m23-1023 · 2023 · External reference

Meta-analysis of the efficacy and safety of Finerenone in diabetic kidney disease

10.1159/000521908 · 2022 · External reference

Cardiovascular events with Finerenone in kidney disease and type 2 diabetes

10.1056/nejmoa2110956 · 2021 · External reference

Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis

10.1093/eurheartj/ehab777 · 2022 · External reference

Changes in albuminuria and the effect of finerenone on cardiovascular outcomes: insights from FINEARTS-HF

10.1093/ndt/gfaf116.0475 · 2025 · External reference

Effects of glucose-lowering agents on cardiovascular and renal outcomes in subjects with type 2 diabetes: an updated meta-analysis of randomized controlled trials with external adjudication of events

10.1111/dom.14888 · 2023 · External reference

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

10.1016/s0140-6736(19)31149-3 · 2019 · External reference

Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials

10.1016/s2213-8587(19)30249-9 · 2019 · External reference

Effects of semaglutide on heart failure outcomes in diabetes and chronic kidney disease in the FLOW trial

10.1016/j.jacc.2024.08.004 · 2024 · External reference

Semaglutide and cardiovascular outcomes in obesity without diabetes

10.1056/nejmoa2307563 · 2023 · External reference

Interaction of obesity and central obesity on elevated urinary albumin-to-creatinine ratio

10.1371/journal.pone.0098926 · 2014 · External reference

Tirzepatide associated with reduced albuminuria in participants with type 2 diabetes: pooled post hoc analysis from the randomized active- and placebo-controlled SURPASS-1–5 clinical trials

10.2337/dc24-1773 · 2025 · External reference

Effects of tirzepatide on the clinical trajectory of patients with heart failure, preserved ejection fraction, and obesity

10.1161/circulationaha.124.072679 · 2025 · External reference

Why has it been challenging to modify kidney disease progression in patients with heart failure?

10.1016/j.jacc.2024.08.034 · 2024 · External reference

Therapeutic effects of heart failure medical therapies on standardized kidney outcomes: comprehensive individual participant-level analysis of 6 randomized clinical trials

10.1161/circulationaha.124.071110 · 2024 · External reference

Cardiovascular-kidney-metabolic overlap in heart failure with mildly reduced or preserved ejection fraction: a trial-level analysis

10.1016/j.jacc.2024.05.005 · 2024 · External reference

11. chronic kidney disease and risk management: standards of care in diabetes—2025

10.2337/dc25-s011 · 2025 · External reference

2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines

10.1016/j.jacc.2025.05.007 · 2025 · External reference

2024 ESC guidelines for the management of elevated blood pressure and hypertension: developed by the task force on the management of elevated blood pressure and hypertension of the European Society of Cardiology (ESC) and endorsed by the European Society

10.1093/eurheartj/ehae178 · 2024 · External reference

2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines

10.1161/hyp.0000000000000065 · 2018 · External reference

2020 International Society of Hypertension Global Hypertension practice guidelines

10.1161/hypertensionaha.120.15026 · 2020 · External reference

Biomarkers in heart failure: relevance in the clinical practice

10.1016/j.ijcard.2022.06.039 · 2022 · External reference

State of the art and trends of circulating cancer biomarkers

10.1177/1724600819900512 · 2020 · External reference

Future of biomarkers in acute coronary syndromes: moving toward a multimarker strategy

10.1161/01.cir.0000078080.37974.d2 · 2003 · External reference

Utility of biomarkers in cardiac amyloidosis

10.1016/j.jchf.2020.03.007 · 2020 · External reference

Biomarkers: their potential in the diagnosis and treatment of heart failure

10.3949/ccjm.82.s2.05 · 2015 · External reference

Optimal early diagnosis and monitoring of diabetic kidney disease in type 2 diabetes Mellitus: addressing the barriers to albuminuria testing

10.1177/21501327211003683 · 2021 · External reference

It is time to screen for heart failure: why and how?

10.1016/j.jchf.2022.06.001 · 2022 · External reference

A real-world cohort study on the quality of potassium and creatinine monitoring during initiation of mineralocorticoid receptor antagonists in patients with heart failure

10.1093/ehjqcco/qcy019 · 2018 · External reference

Fulfillment and validity of the kidney health evaluation measure for people with diabetes

10.1016/j.mayocpiqo.2023.07.002 · 2023 · External reference

Estimated prevalence and testing for Albuminuria in US adults at risk for chronic kidney disease

10.1001/jamanetworkopen.2023.26230 · 2023 · External reference

Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial

10.1016/s0140-6736(23)02408-x · 2024 · External reference

Change in albuminuria and GFR as end points for clinical trials in early stages of CKD: a scientific workshop sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency

10.1053/j.ajkd.2019.06.009 · 2020 · External reference

Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials

10.1016/s2213-8587(18)30314-0 · 2019 · External reference

Unresolved reference

External reference

Albuminuria testing in hypertension and diabetes: an individual-participant data meta-analysis in a global consortium

10.1161/hypertensionaha.121.17323 · 2021 · External reference

Primary care detection of chronic kidney disease in adults with type-2 diabetes: the ADD-CKD study (awareness, detection and drug therapy in type 2 diabetes and chronic kidney disease)

10.1371/journal.pone.0110535 · 2014 · External reference

Suboptimal monitoring and management in patients with unrecorded stage 3 chronic kidney disease in real-world settings: insights from REVEAL-CKD

10.1111/eci.14282 · 2024 · External reference

The drivers of non-adherence to albuminuria testing guidelines and the clinical and economic impact of not identifying chronic kidney disease

10.5414/cn111106 · 2023 · External reference

Primary care physicians’ familiarity, beliefs, and perceived barriers to practice guidelines in non-diabetic CKD: a survey study

10.1186/1471-2369-15-64 · 2014 · External reference

Albuminuria: an underappreciated risk factor for cardiovascular disease

10.1161/jaha.123.030131 · 2024 · External reference

Clinical decision support tools in the electronic medical record

10.1016/j.ekir.2023.10.019 · 2024 · External reference

The disease awareness innovation network” for chronic kidney disease identification in general practice

10.1007/s40620-022-01353-6 · 2022 · External reference

CKD beyond the clinic: a holistic projection of its global burden

10.1016/j.ekir.2025.06.031 · 2025 · External reference

Impact of smartphone-enabled home urinary albumin-to-creatinine ratio testing on Albuminuria screening and management

10.1053/j.ajkd.2025.09.019 · 2025 · External reference

Participation rate and yield of two home-based screening methods to detect increased albuminuria in the general population in The Netherlands (THOMAS): a prospective, randomised, open-label implementation study

10.1016/s0140-6736(23)00876-0 · 2023 · External reference

A real-world precision medicine program including the KidneyIntelX test effectively changes management decisions and outcomes for patients with early-stage diabetic kidney disease

10.1177/21501319231223437 · 2024 · External reference